AbbVie's Humira (adalimumab) approved by Health Canada to treat paediatric patients with chronic non-infectious anterior uveitis

AbbVie

20 February 2019 - The approval marks Humira as the only approved biologic treatment option in Canada for paediatric patients from two years of age with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy.

AbbVie today announced that Health Canada has approved Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in paediatric patients from two years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. HUMIRA is now the only approved biologic treatment option for chronic non-infectious anterior uveitis in children aged two years and older in Canada.

The SYCAMORE clinical trial is a randomised controlled study of the clinical efficacy and safety of Humira combined with methotrexate versus methotrexate plus placebo for the treatment of active JIA-associated uveitis.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Canada , Paediatrics